The Body PRO Covers: The XIV International AIDS Conference

Intensification Therapy With Amprenavir/Ritonavir

July 9, 2002

  • Preliminary Results of Intensification Therapy With Amprenavir (APV)/Ritonavir (RTV) in Two Different Doses: 1,200 (APV)/200 (RTV) QD vs. 600 (APV)/100 (RTV) BID in Heavily Pretreated Patients Failing HAART (TuPeB4580)
    Authored by J. Mallolas, J.L. Blanco, M. Sarasa, M. Arnedo, A. Milinkovic, Y. Lopez-Pua, E. Martinez, J. Murillas, M. Garcia, T. Pumarola, X. Carne, J.M. Gatell
    View the original abstract

Blanco and colleagues from Barcelona, Spain reported their results of a small study looking at the use of either 1,200 amprenavir/200 ritonavir QD (n = 10) or 600 amprenavir/200 ritonavir BID (n = 11) in patients failing a protease inhibitor-based regimen. The median viral load at the time of switch to the amprenavir/ritonavir regimen was 4.1 log while the CD4 count was lower in the BID group (184 versus 326). The study was very small and results for only 13 of the patients were available at 24 weeks of treatment. None of five BID patients and 4/8 of the QD patients had RNA levels less than 200 copies/ml at 24 weeks. Virtual phenotype and number of protease inhibitor mutations seemed to predict virologic activity. Though the authors concluded that the QD regimen was superior, I would take issue with that considering the limited number of patients, the short term of observation and the lower CD4 count for the BID group at baseline.

Previous Session | Next

Tell us what you think of The Body's conference coverage!

This article was provided by TheBodyPRO. It is a part of the publication The XIV International AIDS Conference.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.